Suchergebnisse - "СИРИЙСКАЯ АРАБСКАЯ РЕСПУБЛИКА"

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Geographisches Schlagwort: USPU

    Relation: Политическая лингвистика. 2017. № 6 (66)

  9. 9

    Geographisches Schlagwort: USPU

    Relation: Политическая лингвистика. 2017. № 5 (65)

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Quelle: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 2 (2023); 186-195 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 2 (2023); 186-195 ; 2070-4933 ; 2070-4909

    Dateibeschreibung: application/pdf

    Relation: https://www.pharmacoeconomics.ru/jour/article/view/812/471; Jacobsen M.M., Walensky R.P. Modeling and cost-effectiveness in HIV prevention. Current HIV/AIDS Rep. 2016; 13 (1): 64–75. https://doi.org/10.1007/s11904-016-0303-2.; Joulaei H., Shooshtarian S., Dianatinasab M. Is UNAIDS 90-90-90 target a dream or a reality for Middle East and North Africa Region on ending the AIDS epidemic? A review study. AIDS Rev. 2018; 20 (2): 83–93. https://doi.org/10.24875/AIDSRev.M18000020.; UNAIDS. Middle East and North Africa. Regional report 2018. URL: https://open.unaids.org/sites/default/files/documents/MENA_Regional%20report_2018.pdf (дата обращения 04.05.2023).; Bozicevic I., Reidner G., Haghdoost A. HIV case reporting in the countries of North Africa and the Middle East. J Int AIDS Soc. 2014; 17 (1): 18962. https://doi.org/10.7448/IAS.17.1.18962.; van Marle G., Church D.L., van der Meer F., Gill M.J. Combating the HIV reservoirs. Biotechnol Genet Eng Rev. 2018; 34 (1): 76–89. https://doi.org/10.1080/02648725.2018.1471641.; Bos J.M., Postma M.J., Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics. 2005; 23 (7): 639–49. https://doi.org/10.2165/00019053-200523070-00001.; Boyd M.A., Boffito M., Castagna A., Estrada V. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med. 2019; 20 (Suppl. 1): 3–11. https://doi.org/10.1111/hiv.12708.; Gao C., Meng J., Xiao X., et al. Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis. Int J Nurs Sci. 2020; 7 (2): 238–47. https://doi.org/10.1016/j.ijnss.2020.03.007.; Taylor B.S., Tieu H.V., Jones J., Wilkin T.J. CROI 2019: advances in antiretroviral therapy. Top Antivir Med. 2019; 27 (1): 50–68.; Bigna J.J., Plottel C.S., Koulla-Shiro S. Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infect Dis Poverty. 2016; 5 (1): 85. https://doi.org/10.1186/s40249-016-0179-9.; WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. URL: https://www.who.int/publications/i/item/9789241503006 (дата обращения 04.05.2023).; Chaudhary M.A., Elbasha E.H., Kumar R.N., Nathanson E.C. Cost-effectiveness of raltegravir in HIV/AIDS. Expert Rev Pharmacoecon Outcomes Res. 2011; 11 (6): 627–39. https://doi.org/10.1586/erp.11.79.; Cusato J., Allegra S., Nicolò A., et al. Precision medicine for HIV: where are we? Pharmacogenomics. 2018; 19 (2): 145–65. https://doi.org/10.2217/pgs-2017-0123.; Hester E.K., Astle K. Dolutegravir-rilpivirine, dual antiretroviral therapy for the treatment of HIV-1 infection. Ann Pharmacother. 2019; 53 (8): 860–6. https://doi.org/10.1177/1060028019831674.; Giacomelli A., Conti F., Pezzati L., et al. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. BMC Infect Dis. 2021; 21 (1): 595. https://doi.org/10.1186/s12879-021-06304-3.; Patel D.A., Snedecor S.J., Tang W.Y., et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PLoS One. 2014; 9 (9): e105653. https://doi.org/10.1371/journal.pone.0105653.; Cahn P., Madero J.S., Arribas J.R., et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019; 393 (10167): 143–55. https://doi.org/10.1016/S0140-6736(18)32462-0.; Burch L.S., Smith C.J., Phillips A.N., et al. Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review. AIDS. 2016; 30 (8): 1147–62. https://doi.org/10.1097/QAD.0000000000001068.; Davis W., Mantsios A., Karver T., et al. “It made me more confident that I have it under control”: patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. PLoS One. 2020; 15 (5): e0232473. https://doi.org/10.1371/journal.pone.0232473.; Hidalgo-Tenorio C., Cortés L.L., Gutiérrez A., et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore). 2019; 98 (32): e16813. https://doi.org/10.1097/MD.0000000000016813.; Vitoria M., Hill A., Ford N., et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018; 32 (12): 1551–61. https://doi.org/10.1097/QAD.0000000000001845.; https://www.pharmacoeconomics.ru/jour/article/view/812

  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20